XOMA Royalty’s Post

View organization page for XOMA Royalty, graphic

5,119 followers

Sildenafil Cream 3.6% was one of the three royalty interests we acquired at the end of April in a royalty transaction with Daré Bioscience, Inc. The Phase 2b study results were published in the premiere publication for OBGYNs, Obstetrics & Gynecology. We look forward to Daré’s progress toward initiating a Phase 3 study with this first-in-category asset for female sexual arousal disorder (FSAD).    #SildenafilCream #FSAD #FemaleSexualArousalDisorder #royalty #RoyaltyInterest #RoyaltyAcquisition #ClinicalData #ObstetricsandGynecology #AmericanCollegeofObstetriciansandGynecologists #ACOG

View organization page for Daré Bioscience, Inc., graphic

4,063 followers

We are pleased to announce the publication of our Phase 2b study efficacy results of topical Sildenafil Cream 3.6%, which is being developed for the treatment of female sexual arousal disorder (FSAD), in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists (ACOG). The Phase 2b clinical study showed that topical Sildenafil Cream improved outcomes among women with FSAD, most significantly in a subset of women both with and without concomitant decreased desire. In an exploratory post-hoc analysis of this group, topical Sildenafil Cream significantly increased sexual arousal sensation and reduced sexual distress, as well as improved desire and orgasm. Access the full published study manuscript here: https://bit.ly/3VRh3aA

Preliminary Efficacy of Topical Sildenafil Cream for the... : Obstetrics & Gynecology

Preliminary Efficacy of Topical Sildenafil Cream for the... : Obstetrics & Gynecology

journals.lww.com

To view or add a comment, sign in

Explore topics